ITIF Search

The Critical Role of Biopharmaceutical Startups in Driving Life Sciences Innovation

The Critical Role of Biopharmaceutical Startups in Driving Life Sciences Innovation
Thursday, July 16, 2020 - 12:00 PM to Friday, July 17, 2020 - 12:59 PM EDT
Video Webinar

Event Summary

The COVID-19 crisis has highlighted the critical role that biopharmaceutical innovation plays in our lives, including the role of young biopharma companies, which actually account for two-thirds of all biopharmaceutical enterprises, in developing testing, treatments, and vaccines. The U.S. is fortunate to have the world’s most vibrant ecosystem for life-sciences innovation, supported by a range of robust policies, including strong intellectual property protection, robust federal funding of early-stage research, a strong drug approval system and a drug payment system that supports innovation. This system is already paying dividends as America grapples with COVID-19. But, as they say, past performance is no guarantee of future results, especially if U.S. policy weakens critical success factors.

Marking the release of a new report, ITIF hosted a discussion with experts and leaders from leading biopharmaceutical startups to discuss current challenges and opportunities, and what the federal government should and should not do to maintain this unique American strength.


Stephen Ezell@sjezell
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Information Technology and Innovation Foundation
Sally Allain@SJAllain
Regional Head
JLABS @ Washington, DC
David Beier
Managing Director
Bay City Capital
Trevor R.F.
Trevor R.F. Smith
Director of R&D
Inovio Pharmaceuticals
Back to Top